{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"12","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients surviving at least 14 days after transplant will be evaluable for this endpoint. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase II"}],"paramType":"MEDIAN","populationDescription":"All patients who received treatment and survived at least 14 days after transplant","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) through 1 year post transplant","title":"Phase II - Time to Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"days"}